Measurement tools ARC administered (face to face interview) | Time point | ||||
---|---|---|---|---|---|
At baseline | Each month | After 3 month | After 6 months | ||
Demographics and general medical history | Age, gender, comorbidities | * | |||
Socioeconomic status | Education, income, employment, family characteristics | * | |||
Diagnosis | Cancer type, stage | * | |||
Autonomy | OMS score [55] | * | * | * | * |
Treatment Delivery | RDI ratio [30] Morisky questionnaire [56] MEMs (only for targeted therapy) [57] | * | * | ||
Toxic effects | NCI-CTC-AE (CTCAE v4.0) | * | * | ||
Overall Survival | OS | * | |||
Progression Free Survival | PFS | * | |||
Tumor response | RECIST [58] | * | |||
Quality of life | EORT QLQ-C30 [59] | * | * | ||
Patient experience Satisfaction | PACIC [60] | * |